{"entity":{"id":"sgm-101","kind":"drug","name":"SGM-101","aka":[],"tldr":"SGM-101 is an experimental monoclonal antibody from Surgimab in phase 3 trials for colorectal cancer, aimed at CEACAM5.","summary":"SGM-101 is a monoclonal antibody developed by Surgimab. Its target is CEACAM5 (the sponsor names CEA (carcinoembryonic antigen)). The sponsor states: A fluorochrome-labelled anti-CEA monoclonal antibody used as an intraoperative near-infrared imaging agent to delineate primary and recurrent tumour and metastases during surgery. ClinicalTrials.gov describes the intervention as: A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT03659448 (Performance of SGM-101 for the Delineation of Primary and Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer), in colorectal cancer. The largest, NCT03659448, plans to enrol 300 participants with primary completion was scheduled for 2024-11 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of SGM-101","url":"https://clinicaltrials.gov/search?intr=SGM-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["ceacam5"],"drugs":[],"companies":["surgimab"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03659448"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"A fluorochrome-labelled anti-CEA monoclonal antibody used as an intraoperative near-infrared imaging agent to delineate primary and recurrent tumour and metastases during surgery.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sgm-101/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/"}],"company":[{"id":"surgimab","kind":"company","name":"Surgimab","route":"/companies/surgimab/"}],"trial":[{"id":"nct03659448","kind":"trial","name":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","route":"/trials/nct03659448/"}]}}